HMGB1 Promotes Myeloid Egress and Limits Lymphatic Clearance of Malignant Pleural Effusions.
HMGB1
adaptome
benign pleural effusions
immune repertoire
malignant pleural effusions
monocytes
tumor immunology
γδ T cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
02
2020
accepted:
27
07
2020
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
1
5
2021
Statut:
epublish
Résumé
Pleural effusions, when benign, are attributed to cardiac events and suffusion of fluid within the pleural space. When malignant, lymphatic obstruction by tumor and failure to absorb constitutively produced fluid is the predominant formulation. The prevailing view has been challenged recently, namely that the lymphatics are only passive vessels, carrying antigenic fluid to secondary lymphoid sites. Rather, lymphatic vessels can be a selective barrier, efficiently coordinating egress of immune cells and factors within tissues, limiting tumor spread and immune pathology. An alternative explanation, offered here, is that damage associated molecular pattern molecules, released in excess, maintain a local milieu associated with recruitment and retention of immune cells associated with failed lymphatic clearance and functional lymphatic obstruction. We found that levels of high mobility group box 1 (HMGB1) were equally elevated in both benign and malignant pleural effusions (MPEs) and that limited diversity of T cell receptor expressing gamma and delta chain were inversely associated with these levels in MPEs. Acellular fluid from MPEs enhanced γδ T cell proliferation
Identifiants
pubmed: 33013860
doi: 10.3389/fimmu.2020.02027
pmc: PMC7498625
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
HMGB1 Protein
0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2027Subventions
Organisme : NCI NIH HHS
ID : R01 CA181450
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206012
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Informations de copyright
Copyright © 2020 Soloff, Jones, Powers, Murthy, Wang, Russell, Byrne-Steele, Lund, Yuan, Monaco, Han, Dhupar and Lotze.
Références
Vet Immunol Immunopathol. 2012 Jun 15;147(1-2):1-5
pubmed: 22520944
Methods Mol Biol. 2020;2055:369-397
pubmed: 31502161
Nat Commun. 2015 Dec 08;6:8726
pubmed: 26644347
Cell. 2016 Sep 22;167(1):203-218.e17
pubmed: 27641500
Nat Rev Immunol. 2005 Apr;5(4):331-42
pubmed: 15803152
Cancer Res. 2012 Apr 15;72(8):1996-2005
pubmed: 22345153
Curr Opin Immunol. 2008 Oct;20(5):518-23
pubmed: 18599281
Sci Transl Med. 2018 Sep 5;10(457):
pubmed: 30185651
Cancer Growth Metastasis. 2015 Jul 23;8:25-34
pubmed: 26279628
Immunobiology. 2009;214(4):303-9
pubmed: 19201506
J Immunol. 2004 Jul 1;173(1):307-13
pubmed: 15210788
Oncoimmunology. 2017 Feb 17;6(4):e1293210
pubmed: 28507797
J Immunol. 2005 Jun 15;174(12):7506-15
pubmed: 15944249
Leukemia. 2011 Jan;25(1):23-31
pubmed: 20927132
Mol Immunol. 2013 Aug;55(1):76-82
pubmed: 23207101
J Exp Med. 2011 Mar 14;208(3):491-503
pubmed: 21383056
Am J Respir Cell Mol Biol. 2019 Aug;61(2):130-131
pubmed: 30958972
Cancer Res. 2012 Jan 1;72(1):230-8
pubmed: 22102692
J Appl Physiol (1985). 1990 Jun;68(6):2623-30
pubmed: 2384440
Front Immunol. 2015 Feb 04;6:37
pubmed: 25699053
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1518-23
pubmed: 20080641
Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2829-33
pubmed: 7511820
Nat Rev Cancer. 2019 Jul;19(7):392-404
pubmed: 31209264
Cancer Res. 2012 Aug 15;72(16):3967-76
pubmed: 22700877
Oncoimmunology. 2019 Jan 22;8(4):e1554969
pubmed: 30906651
Am J Respir Crit Care Med. 2014 Mar 15;189(6):626-7
pubmed: 24628311
J Clin Invest. 2016 Sep 1;126(9):3389-402
pubmed: 27525437
Am J Respir Cell Mol Biol. 2019 Aug;61(2):174-184
pubmed: 30608868
Front Immunol. 2013 Mar 20;4:68
pubmed: 23519706
Oral Oncol. 2012 May;48(5):409-16
pubmed: 22265157
Cytokine Growth Factor Rev. 2006 Jun;17(3):189-201
pubmed: 16513409
Int J Cancer. 2018 Jun 1;142(11):2234-2243
pubmed: 29318605
Chest. 1987 Dec;92(6):967-70
pubmed: 3677841
Cancer Immunol Immunother. 1994 Oct;39(4):239-48
pubmed: 7954526
Anticancer Res. 2009 Dec;29(12):5013-7
pubmed: 20044610
Cancer Immunol Res. 2020 Jan;8(1):146-154
pubmed: 31719056
Science. 2015 Aug 7;349(6248):606-613
pubmed: 26160376
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Int J Cancer. 1996 Apr 10;66(2):201-8
pubmed: 8603812
J Natl Compr Canc Netw. 2012 Aug;10(8):975-82
pubmed: 22878823
Cell Rep. 2017 Sep 26;20(13):3176-3187
pubmed: 28954233
Cancer Res. 2011 Jul 15;71(14):4821-33
pubmed: 21602432
J Appl Physiol (1985). 1988 Jan;64(1):384-90
pubmed: 3356657
Clin Cancer Res. 1997 Jan;3(1):47-50
pubmed: 9815536
Am J Respir Crit Care Med. 2014 Mar 15;189(6):697-706
pubmed: 24410406
J Transl Med. 2019 Feb 18;17(1):47
pubmed: 30777078
Clin Cancer Res. 2013 Aug 1;19(15):4046-57
pubmed: 23723299
J Appl Physiol (1985). 1988 Aug;65(2):585-93
pubmed: 3170409
J Thorac Dis. 2015 Jun;7(6):1021-30
pubmed: 26150915
Front Immunol. 2019 Jul 11;10:1561
pubmed: 31379812
Pathobiology. 2009;76(4):155-62
pubmed: 19571604
Oncol Lett. 2017 Jul;14(1):1133-1140
pubmed: 28693285
Respir Physiol Neurobiol. 2020 Jan;272:103330
pubmed: 31639457
Acta Cardiol Sin. 2018 Sep;34(5):399-408
pubmed: 30271090
Int Immunol. 2012 Aug;24(8):485-94
pubmed: 22473704
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31727783
Cancer Res. 2013 Jan 15;73(2):629-39
pubmed: 23108142
J Clin Invest. 1988 Oct;82(4):1422-9
pubmed: 3170750